Chinese Firms Bag Most Latest Volume-Based Purchasing Wins
Domestics Favored Over Multinationals?
Domestic companies have won most of the bids in China's latest government procurement round for 62 drugs, marking an end to the previous dominance of off-patent products from multinationals.
You may also be interested in...
The value-based procurement scheme in China is about to be implemented on insulin products and while most of Novo Nordisk's therapies were included in the tender, price cuts are going to impact global sales growth by 3% next year.
China has signaled that it will offer a more level playing field to foreign players as part of a bid to join a major regional trade pact but some see the gesture as offering little real relief and high hurdles remain.
To ensure the Beijing Winter Olympics is a smooth affair, the Chinese government has ordered partial or complete halts in industrial production in some provinces from late November until mid-March, disrupting an already fragile global pharma active ingredient supply chain. The emergence of the Omicron coronavirus variant is just adding to the complexities.